Navidea says NAV4694 clinical study is done

01/15/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals has announced the completion of a clinical trial of its NAV4694 radiopharmaceutical, a biomarker used to identify cerebral beta amyloid in potential Alzheimer's disease cases. Results of the study, which was intended to determine the safety and efficacy of the biomarker when used with PET imaging, will be presented at this year's SNMMI Annual Meeting. Researchers are planning for a Phase III study of the agent this year. Meanwhile, Navidea said it has also secured rights to two other beta amyloid PET imaging agents from AstraZeneca: AZD2184 and AZD2995.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT